

## PERSONAL INFORMATION

**Giovanni Fagà**

## WORK EXPERIENCE

---

2020 - present

### **Head of Automation**

Fondazione Human Technopole, Milan (Italy)

Neurogenomics Research Centre - Automated Stem Cell and Organoid Facility

2016–2020

### **Senior Scientist**

IFOM - the FIRC Institute of Molecular Oncology Foundation - Experimental Therapeutics Unit, Milano (Italy) –

Senior investigator of the Assay Development and Automation unit:

- Coordinate activities aimed at design, development, validation and pilot screening of biological and biochemical high-throughput assays.
- Development of assay panels supporting HTS hit validation and Structure-Activity Relationship (SAR) studies.
- Convert low-throughput lab protocols into plate-based medium-to-HTS assays

2009–2016

### **Scientist**

European Institute of Oncology (IEO) - Drug Discovery Unit, Milano (Italy)

Team leader of the Assay Development unit

2003–2008

### **PhD fellowship in Molecular Biology**

European Institute of Oncology (IEO), Milan (Italy)

2000–2003

### **Researcher**

San Raffaele Scientific Institute, DIBIT, Milan (Italy)

- Basic research on HIV-1 molecular virology

1997–2000

### **Researcher**

Don Carlo Gnocchi Foundation, I.R.C.C.S., Milan (Italy)

- Study the role of Poliovirus in the generation of neoplastic and/or demyelinating disease of the CNS.

## EDUCATION AND TRAINING

---

2016

### **Venus Software and Script Language - Training Course**

HAMILTON

2011

### **Freedom EVOware - Training Course**

TECAN

2008–2009

### **Specialization Master in Intellectual Property**

Università degli Studi di Milano, Milan (Italy)

2003–2008

### **PhD in Molecular Biology**

European Institute of Oncology (IEO), Milan (Italy)

- Thesis title: *Myc interactions with components of the WNT signaling pathway.*

## 1992–1997 **Master Degree in Biological Sciences**

Università degli Studi di Milano, Milan (Italy)

- Final overall score: 110/110 cum laude.

### PERSONAL SKILLS

---

**Communication skills** Gained an excellent communication expertise in conveying ideas and complex information to an audience, both in oral and written presentations. Developed the ability to write clear and concise reports, mastering the use of statistics and graphs.

**Organisational / managerial skills** In the last five years I successfully coordinated a team of scientist and technicians, developing decision-making skill and the ability to handle multiple projects concurrently.

**Job-related skills** Extensive expertise in assay design, screening automation & technology platforms, data analysis and state-of-the-art detection platforms.

I have a well-founded knowledge of Automated Liquid Handling Platforms, particularly of Tecan and Hamilton instruments (and the correlated scripting languages). I supervised the design and setup of the Automated Hamilton Workstation currently working under my responsibility.

In the past few years, I managed the development of:

- HTS for the identification of the Numb protein regulators using an ELISA protocol adapted for automation in 384 well plates
- In vitro demethylation assay for KDM1 and JMJ family members (TR-FRET, Alpha Screen)
- Kinase assays (ATP-Glo)
- Cell proliferation assays (CellTiter-Glo, CellTiter-Fluo, Resazurin,...)
- Fluorescent Polarization assays aimed at identifying inhibitors of Protein-Protein interactions.

Moreover, I supervised the setup of a gene expressions assay (using both RT-qPCR and OpenArray platforms) as a primary screening tool to be used in an HTS on induced Pluripotent Stem Cells (iPSCs).

I am capable and confident in a wide number of molecular, biochemical, viral and cellular biology protocols.

**Computer skills** Microsoft Office Suite - Apple iWork - Open Office - Adobe Creative Suite - Graphpad Prism (All versions).

Mastery of Assay Explorer and Isentris (Accelerys - Biovia) as Laboratory Information Management System (LIMS). Deep knowledge of scripting languages for Tecan and Hamilton environments.

I have gained basic skills in Python programming language, VBA for Excel and mySQL.

**Languages** My first language is Italian. I am also capable to speak, write and understand English clearly without major concerns.

## ADDITIONAL INFORMATION

### Patents

- Patent no. WO/2011/073929
- “HECT E3 LIGASE NEDD4 INHIBITORS AND USES THEREOF” submitted

### Publications

Atashpaz S, Samadi Shams S, Gonzalez JM, Sebestyén E, Arghavanifard N, Gnocchi A, Albers E, Minardi S, Faga G, Soffientini P, Allievi E, Cancila V, Bachi A, Fernández-Capetillo Ó, Tripodo C, Ferrari F, López-Contreras AJ, Costanzo V. ATR expands embryonic stem cell fate potential in response to replication stress. *Elife*. 2020 Mar 12;9.

Vianello P, Sartori L, Amigoni F, Cappa A, Fagà G, Fattori R, Legnaghi E, Ciossani G, Mattevi A, Meroni G, Moretti L, Cecatiello V, Pasqualato S, Romussi A, Thaler F, Trifiró P, Villa M, Botrugno OA, Dessanti P, Minucci S, Vultaggio S, Zagarrí E, Varasi M, Mercurio C. Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity Relationship. *J Med Chem*. 2017 Mar 9;60(5):1693-1715.

Sartori L, Mercurio C, Amigoni F, Cappa A, Fagà G, Fattori R, Legnaghi E, Ciossani G, Mattevi A, Meroni G, Moretti L, Cecatiello V, Pasqualato S, Romussi A, Thaler F, Trifiró P, Villa M, Vultaggio S, Botrugno OA, Dessanti P, Minucci S, Zagarrí E, Carettoni D, Iuzzolino L, Varasi M, Vianello P. Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 1: High-Throughput Screening and Preliminary Exploration. *J Med Chem*. 2017 Mar 9;60(5):1673-1692.

Sabò A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, Morelli MJ, Bora P, Doni M, Verrecchia A, Tonelli C, Fagà G, Bianchi V, Ronchi A, Low D, Müller H, Guccione E, Campaner S, Amati B. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. *Nature*. 2014 Jul 24;511(7510):488-492.

Sanchez-Arévalo Lobo VJ, Doni M, Verrecchia A, Sanulli S, Fagà G, Piontini A, Bianchi M, Conacci-Sorrell M, Mazarrol G, Peg V, Losa JH, Ronchi P, Ponzoni M, Eisenman RN, Dogliani C, Amati B. Dual regulation of Myc by Abl. *Oncogene*. 2013 Nov 7;32(45):5261-71

Perna D, Fagà G, Verrecchia A, Gorski MM, Barozzi I, Narang V, Khng J, Lim KC, Sung WK, Sanges R, Stupka E, Oskarsson T, Trumpp A, Wei CL, Müller H, Amati B. Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. *Oncogene*. 2012 Mar 29;31(13):1695-709.

Müller J, Samans B, van Riggelen J, Fagà G, Peh K N R, Wei CL, Müller H, Amati B, Felsher D, Eilers M. TGFβ-dependent gene expression shows that senescence correlates with abortive differentiation along several lineages in Myc-induced lymphomas. *Cell Cycle*. 2010 Dec 1;9(23):4622-6.

Campaner S, Doni M, Verrecchia A, Fagà G, Bianchi L, Amati B. Myc, Cdk2 and cellular senescence: Old players, new game. *Cell Cycle*. 2010 Sep 15;9(18):3655-61. Epub 2010 Sep 15.

Smith AP, Verrecchia A, Fagà G, Doni M, Perna D, Martinato F, Guccione E, Amati B. A positive role for Myc in TGFβ-induced Snail transcription and epithelial-to-mesenchymal transition. *Oncogene*. 2009 Jan 22;28(3):422-30.

Voena C, Malnati M, Majolino I, Fagà G, Montefusco V, Farina L, Santoro A, Ladetto M,

Boccardo M, Corradini P. Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. *Bone Marrow Transplant.* 2003 Oct;32(8):791-3.

Grivel JC, Santoro F, Chen S, Fagà G, Malnati MS, Ito Y, Margolis L, Lusso P. Pathogenic effects of human herpesvirus 6 in human lymphoid tissue ex vivo. *J Virol.* 2003 Aug;77(15):8280-9.

Grivel JC, Ito Y, Fagà G, Santoro F, Shaheen F, Malnati MS, Fitzgerald W, Lusso P, Margolis L. Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. *Nat Med.* 2001 Nov;7(11):1232-5.

Van den Bosch G, Locatelli G, Geerts L, Fagà G, Ieven M, Goossens H, Bottiger D, Oberg B, Lusso P, Berneman ZN. Development of reverse transcriptase PCR assays for detection of active human herpesvirus 6 infection. *J Clin Microbiol.* 2001 Jun;39(6):2308-10.